Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBT Margin (2022 - 2026)

Axsome Therapeutics' EBT Margin history spans 5 years, with the latest figure at 33.76% for Q1 2026.

  • On a quarterly basis, EBT Margin rose 1516.0% to 33.76% in Q1 2026 year-over-year; TTM through Mar 2026 was 26.66%, a 6196.0% increase, with the full-year FY2025 number at 28.77%, up 4567.0% from a year prior.
  • EBT Margin hit 33.76% in Q1 2026 for Axsome Therapeutics, down from 14.35% in the prior quarter.
  • Over the last five years, EBT Margin for AXSM hit a ceiling of 9.13% in Q1 2023 and a floor of 14965.4% in Q4 2024.
  • Historically, EBT Margin has averaged 1047.2% across 5 years, with a median of 91.09% in 2024.
  • Biggest five-year swings in EBT Margin: plummeted -1482703bps in 2024 and later skyrocketed 1495105bps in 2025.
  • Tracing AXSM's EBT Margin over 5 years: stood at 251.29% in 2022, then skyrocketed by 45bps to 138.37% in 2023, then crashed by -10716bps to 14965.4% in 2024, then soared by 100bps to 14.35% in 2025, then crashed by -135bps to 33.76% in 2026.
  • Business Quant data shows EBT Margin for AXSM at 33.76% in Q1 2026, 14.35% in Q4 2025, and 27.62% in Q3 2025.